MCC950 Struktur

MCC950

Bezeichnung:MCC950

CAS-Nr210826-40-7

Englisch Name:MCC950

CBNumberCB52744215

SummenformelC20H24N2O5S

Molgewicht404.48

MOL-Datei210826-40-7.mol

MCC950 physikalisch-chemischer Eigenschaften

Schmelzpunkt	239 °C
Dichte	1.396±0.06 g/cm3(Predicted)
storage temp.	-20°C
Löslichkeit	Soluble in DMSO (up to 40 mg/ml) or in Water (up to 30 mg/ml)
Aggregatzustand	solid
pka	4.74±0.10(Predicted)
Farbe	White
Stabilität	Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 1 month.

MCC950 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
MCC-950 (210826-40-7) was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-1.1?Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes.2?MCC-950 blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations.3?Inhibits interleukin 1β (IL-1β) secretion?in vivo?and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model).3?Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome.4?MCC-950 is a valuable new tool for exploring the pathophysiology of NLRP3.
Verwenden
MCC950 selectively inhibits pyrin domain-containing protein 3 (NLRP3) inflammasome, a protein complex involved in the inflammatory process (1). The NLRP3 inflammasome is related to a wide range of immune disorders such as multiple sclerosis, inflammatory bowel disease, auto-immune and auto-inflammatory diseases (2). MCC950 has been shown to specifically inhibit the activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes (1). MCC950 is a potential therapeutic for NLRP3-associated syndromes.
Einzelnachweise
1) Laliberte?et al.?(2003),?Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing; J. Biol. Chem.,?278?16567 2) Coll?et al. (2011),?The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes; Clin. PLoS One,?6(12)?e29539 3) Coll?et al.?(2015),?A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory disease; Nat. Med.,?21?248 4) Kaneko?et al.?(2015),?Reconstituted AIM2 inflammasome in cell-free system; J. Immunol. Methods,?426?76

MCC950 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

210826-40-7, MCC950 Verwandte Suche:

Send Inquriy